HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 655 participants.
Also called NCT04153149
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 655 participants
- Sponsor
- Registry
-
NCT04153149 -
2023-508366-15-00
-
- Other papers using this trial's data
- Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B
- Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial
- Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis With Cardiomyopathy
- Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B
- Influence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis
- Left Atrial Structure and Function, Clinical Outcomes, and Efficacy of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: A Secondary Analysis of the HELIOS-B Randomized Clinical Trial
- Outpatient Worsening Heart Failure in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial
- Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Secondary Analysis of the HELIOS-B Randomized Clinical Trial
- Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Canada, Colombia, Croatia, Czechia, Denmark, France, Germany, Hungary, Ireland, Israel, Japan, Latvia, Lebanon, Lithuania, Malaysia, Moldova, Netherlands, Norway, Peru, Poland, Portugal, Saudi Arabia, Slovenia, South Korea, Spain, Sweden, Thailand, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04153149. Randomized; quadruple masking; primary purpose treatment. Start 2019-11-26 (actual); primary completion 2024-05-08 (actual). Results posted on 2025-10-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Condition
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- Intervention (Drug)
- Vutrisiran
- Intervention (Drug)
- Sterile Normal Saline (0.9% NaCl)
- Lead sponsor
- Alnylam Pharmaceuticals
Record details
- Record id
cardio:ct-nct04153149- Content hash
e1f228daa32caf58a527782ad2f43f6f761825e70700e025fe58ddc0da70b362